{"id":666041,"date":"2026-05-12T13:03:25","date_gmt":"2026-05-12T13:03:25","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/666041\/"},"modified":"2026-05-12T13:03:25","modified_gmt":"2026-05-12T13:03:25","slug":"glp-1-drugs-may-reshape-how-brain-values-rewarding-foods","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/666041\/","title":{"rendered":"GLP-1 drugs may reshape how brain values rewarding foods"},"content":{"rendered":"<p>A new study from the University of Virginia reveals that a widely used class of weight-loss drugs does more than suppress appetite-it directly alters brain circuits that control motivation and reward.<\/p>\n<p>Published in Nature, the research led by UVA neuroscientist Ali D. G\u00fcler shows that newer oral GLP-1 drugs can influence how the brain values food, helping explain both their effectiveness and their sometimes unexpected side effects.<\/p>\n<p>&#8220;These drugs are incredibly effective,&#8221; G\u00fcler said. &#8220;But what we wanted to understand is what they&#8217;re doing in the brain.&#8221;<\/p>\n<p>Key findings<\/p>\n<p>&#13;<br \/>\n\tGLP-1 drugs act not only on metabolic pathways but also on brain circuits linked to reward&#13;<br \/>\n\tResearchers identified a pathway connecting the hindbrain, central amygdala and dopamine-producing neurons&#13;<br \/>\n\tThe drugs reduce not just hunger, but the desire for high-calorie, rewarding foods&#13;<br \/>\n\tFindings may help explain both therapeutic benefits and side effects such as nausea or reduced pleasure&#13;<\/p>\n<p>Beyond appetite suppression<\/p>\n<p>GLP-1 receptor agonists were originally developed to treat Type 2 diabetes by improving insulin response, with weight loss emerging as a secondary benefit. The UVA team sought to better understand how these drugs work in the brain.<\/p>\n<p>Using a genetically engineered mouse model, the researchers demonstrated that newer small-molecule GLP-1 drugs-such as recently approved oral medications-can reach deep brain regions. Scientists have long known that GLP-1 drugs act on neurons in the hindbrain, contributing to feelings of fullness and nausea. The UVA team found that, in addition to those established effects, the drugs also engage a separate circuit linking the hindbrain to the central amygdala and ultimately to dopamine-producing neurons.<\/p>\n<p>This pathway plays a critical role in how the brain assigns value to rewarding experiences, including high-calorie foods.<\/p>\n<p>&#8220;What we show is that these drugs can reduce not just hunger, but the desire to pursue rewarding food,&#8221; G\u00fcler said. &#8220;They&#8217;re acting on the system that makes you want the cake, not just the system that makes you feel full.&#8221;<\/p>\n<p>The findings also help explain differences among drugs in this rapidly growing class. Some compounds appear to produce more nausea-like effects, while others create a brain state that reduces food motivation without the same level of discomfort.<\/p>\n<p>Implications for medicine, industry and society<\/p>\n<p>The discovery comes as pharmaceutical companies race to develop more accessible alternatives to injectable GLP-1 therapies. Oral versions are easier to produce, more stable and significantly less expensive-potentially expanding access to millions of patients worldwide.<\/p>\n<p>At the same time, the findings raise broader questions about how these drugs may affect behavior.<\/p>\n<p>&#8220;If these drugs are affecting reward pathways in the brain, that has implications beyond weight loss,&#8221; G\u00fcler said. &#8220;It could influence things like addiction, impulse control or even how people experience pleasure.&#8221;<\/p>\n<p>Early evidence suggests some patients may find it easier to reduce compulsive behaviors, such as smoking, while others report a diminished sense of enjoyment. G\u00fcler said both outcomes underscore the need for deeper study.<\/p>\n<p>&#8220;As scientists, our job is not just to say that something works,&#8221; he said. &#8220;It&#8217;s to understand how it works, so we can improve it and anticipate unintended consequences.&#8221;<\/p>\n<p>He added that as these medications become more widely used, careful oversight will be essential.<\/p>\n<p>&#8220;These are powerful compounds,&#8221; G\u00fcler said. &#8220;We need to understand them fully as they move into everyday use.&#8221;<\/p>\n<p>Next steps<\/p>\n<p>G\u00fcler and his team are continuing to study how these brain circuits function and how different drugs may target them more precisely.<\/p>\n<p>&#8220;This is just the beginning,&#8221; he said. &#8220;If we understand these pathways, we may be able to design treatments that target specific behaviors-whether that&#8217;s overeating, addiction or something else entirely.&#8221;<\/p>\n<p>As GLP-1 drugs become more widely used, researchers say understanding their full neurological impact will be critical.<\/p>\n<p>&#8220;This is about knowing what these drugs are really doing,&#8221; G\u00fcler said. &#8220;The more we understand, the better we can make them-for patients and for society.&#8221;<\/p>\n<p>The research was supported by internal funding from the University of Virginia, including its Brain Institute and Arts &amp; Sciences programs.<\/p>\n","protected":false},"excerpt":{"rendered":"A new study from the University of Virginia reveals that a widely used class of weight-loss drugs does&hellip;\n","protected":false},"author":2,"featured_media":812,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[33],"tags":[6116,107222,24232,64,63,1362,38543,1730,1295,137,490,83462,1368,61545,337,555],"class_list":["post-666041","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-addiction","tag-amygdala","tag-appetite","tag-au","tag-australia","tag-brain","tag-dopamine","tag-drugs","tag-food","tag-health","tag-medication","tag-nausea","tag-neurons","tag-oral","tag-research","tag-weight-loss"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/666041","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=666041"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/666041\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/812"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=666041"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=666041"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=666041"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}